Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation
European EBIT Plummets By A Third, Further Supply Disruptions Anticipated
Executive Summary
Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.
You may also be interested in...
Fresenius Brings In Transparency Change For Kabi Unit
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO
The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.